Pfizer Stock Forecast: Trending Analysts See Cautious Upside

Pfizer (PFE) stock has risen 2.6% over the past week, 7.1% over the past month, and 8.6% over the last twelve months. Wall Street’s analysts are moderately bullish, with a consensus rating of “ModerateBuy” and an average 12‑month price target of $28.53, implying modest upside from the last closing price of $26.78. For investors, this points to a stock that is grinding higher but still viewed as a cautious opportunity rather than a high-conviction growth story.

One of the latest voices weighing in is Jason Gerberry of Bank of America, who reiterated a Hold (Neutral) stance on Pfizer on February 4, 2026, setting a price objective of $27.00. This target sits only slightly above recent trading levels, signaling limited expected upside in the near term. Gerberry’s view helps anchor the broader analyst narrative: while Pfizer looks inexpensive and offers an appealing dividend yield, the growth story remains clouded by competitive pressures and pipeline uncertainties.

Gerberry’s report noted that Pfizer’s fourth-quarter 2025 earnings did little to change the overall outlook. He made only modest tweaks to revenue forecasts, trimming estimates by about 1% for 2027–2028 and making immaterial changes thereafter. The firm continues to see Pfizer facing difficult growth headwinds through the end of the decade. Despite the company trading at a low earnings multiple and providing an attractive yield, Gerberry believes limited new product launches and a lack of near-term pipeline catalysts are key reasons to stay Neutral rather than turn more bullish.

A major focus of the latest update is Pfizer’s obesity drug program, particularly the Phase 2b VESPER-3 data for MET-097 (also known as PF’3944). Gerberry views the results as validating this candidate as a potentially differentiated long-acting obesity treatment, especially with once‑monthly dosing that appears viable starting from week 12. However, questions still hang over its competitive positioning, including the balance between efficacy and side effects at higher doses, which will be important for monotherapy competitiveness as key readouts are expected around 2027. While Pfizer also has oral and amylin-injectable combination obesity programs, these are seen as less de‑risked and more likely to reach the market after 2030.

Overall, Gerberry remains Neutral on Pfizer, arguing that the company’s strong dividend yield—over 6%, in his view—supports the share price but does not fully compensate for looming loss-of-exclusivity pressures and lingering weakness in the COVID-19 franchise. He maintains a $27.00 price objective, based on a 9.5x price-to-earnings multiple applied to his 2027 “underlying” earnings forecast, a slight discount to peers. For investors following analyst performance, Jason Gerberry is a highly ranked voice: this N-star analyst stands at #324 out of 11,984 tracked experts, with a 61.73% success rate and an average return of 15.5% per rating. Never miss a stock rating. Find all the latest ratings on TipRanks’ Top Wall Street Analysts page.